Sequenom Corp fka SQNM

[garza]

Reversal of Fortune for Two Biomed Rivals

LOS ANGELES - May 01, 2009 - Sequenom Inc. (NASDAQ:SQNM) topped the list of biggest percentage price decliners among common stocks
on the Nasdaq Stock Market on Thursday.

Meanwhile, EXACT Sciences (NASDAQ:EXAS) is poised to continue its comeback from penny stock
levels late last year and has a chance to close the year at a higher market value than its molecular
diagnostics rival.

BiomedReports.Com reports on the interesting reversal of fortune for these two rivals whose ties run deep.

Months ago, Sequenom launched a hostile, all-stock tender offer for EXACT Sciences earlier this year for $1.50 per share (which would now be valued at less than 40 cents), but EXACT rejected the deal in favor of a strategic pact with Genzyme (NASDAQ:GENZ) which involved a $24.5M cash infusion.

SQNM was trading around 25 bucks in late January, but published news reports indicate that Sequenom publicized clinical data throughout 2008 and 2009, which it claimed confirmed the strong efficacy of Sequenom's prenatal genetic test for Down syndrome.
On April 29, 2009, Sequenom disclosed "employee mishandling" of the clinical data, which raised "significant concerns regarding the integrity of that data."

In the first hour of trading on Thursday, Sequenom shares plunged 77%, or $11.43, to $3.48 on 27 times its average daily volume over the past 30 days.

A full special report on the companies appears today at:

http://biomedreports.com/articles/most-popular/885-sequenom-splattered-exact-sciences-on-the-rise.html